Moreover, plasma N‐p‐tau181 was 23.4% higher in the A+ group than in A− one (Fig 2E; Table 1), a greater increase than that of plasma NfL (18.0%), the most used AD plasma biomarker to date. This evidence concerns the gene NEFL and Alzheimer disease.